Navigation Links
Indian Prime Minister has successful Knee Replacement Surgery

Mr. Atal Behari Vajpayee, the Prime Minister of India has successfully undergone left knee joint replacement by Dr. Chittaranjan Ranawat at the Breach Candy Hospital in Mumbai. "The operation, which started at around 10 a.m., was completed by 11.15 a.m. and went on very well, to my satisfaction," Dr. Ranawat said at a press briefing. ``He (Mr. Vajpayee) was awake and comfortable throughout the operation and is now in the recovery room. He is not on any sedative. I talked to him after the operation.'' Dr. Ranawat was assisted by two surgeons.
'"/>




Page: 1

Related medicine news :

1. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
2. Indian Doctor granted US patent on organ regeneration
3. Heart attack kills one in every 10 Indians
4. Indian Cherry: Richest Source of Vitiamin C
5. Indian Nationals with Foreign Medical Degrees can now practice in India
6. An Indian Bride with signs of SARS
7. Are Indians aware of SARS ?
8. Indians Stay Away from Coke, Pepsi After Toxin Scare
9. Indian pharma industry upbeat on WTO drug deal
10. Indian Treatment for Iraqi Babies
11. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
Post Your Comments:
(Date:5/16/2008)... Haag,s Statement for National HIV Vaccine Awarene...Newswire/ -- Twenty-six years into the,AIDS epidem...nutes in the,U.S. On Sunday, May 18, HIV Vaccine A...rtners in the National Institute of Allergy and In...ation Initiative, urges everyone,to help end the A...
(Date:5/16/2008)...s determine who would benefit most from chemo afte... (HealthDay News) -- A panel of 15 genes may help ...l cell lung cancer will experience a recurrence an...a new study shows. , By extension, the same ge...ss aggressive forms of the cancer who would be abl...
(Date:5/16/2008)...y 16 /PRNewswire/ -- Huntsworth plc (LSE: HNT), "t...s and healthcare communications,group headquartere...t with,respect to the Group,s performance in the f...8)., The statement follows below., 15 May 2008... Interim Management Statement, ...
(Date:5/16/2008)... year-old Chinese students learn the lesson of hel...huan earthquake, NANJING, China, May 16 /PRNewswi... earthquake, even the youngest members of China ar...ief efforts. All around the,country, schools are r...,Led by the school,s principal, Ms. Zhang Lijun, t...
Breaking Medicine News(10 mins):Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Chinese Preschoolers Participate in Fund Drive to Help the Victims of Sichuan Quake 2
...easing day by day and the mortality rate is also d... to the increasing number of AIDS/HIV patients// U... (UNDP) has appointed 29 HIV/AIDS Counselors. Thi...under the Global Fund for AIDS in Liberia. The ma...
...the case of lung cancer when compared to whites, a...rch findings // .This is in spite of the fact that...males. The disease accounts for the highest number...s are concerned needs to be addressed. Both whites...
...miRNAs) belong to the newly discovered group of ge...h Carolina have discovered two genes // belonging ...ter attributed to the proper development of muscle...e initially discovered (1993) in the genome of the...
...y researchers at the UT Southwestern Medical Cente...damage to the urinary bladder if a woman is coache...thermore, the presence of a coach does not seem to... in terms of shortening labor. The study is the f...
Other Medicine News:Health News:Genetic mystery behind muscle development unraveled. 2Health News:Coaching In Labor Could Increase Bladder Problems 2
(Date:5/15/2008)...icacy Clinical Data from Prostate, Colorectal and ...- Company to Hold Investor Event on Sun., June 1 w...f., May 15 /- Poniard,Pharm...ical company focused,on oncology, today announced ...ical trials of picoplatin, in various tumor types ...
(Date:5/15/2008)...nted amount of research reflects depth and breadth...o develop new treatments for ...ighlight impact of Zometa(R), the leading IV, bisp...-stage breast cancer, - Four oral sessions to fea...ibitor of mTOR, including first results of RECORD-...
(Date:5/15/2008)...N.J., May 15 /- Sanofi-aven...that findings from the,landmark ATHENA study showe... the treatment of patients with atrial fibrillatio...ascular hospitalizations or death from any,cause b...meeting the study,primary endpoint. The ATHENA res...
(Date:5/15/2008)...itzerland, May 15 /- Ergonex Pharma t...g Administration (FDA) has,granted orphan drug des...ry,arterial hypertension (PAH). Terguride is curre... trial in Europe., "The FDA,s grant of orphan dru...strengthens our development program by offering re...
Breaking Medicine Technology:Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Positive Results Published Using AtriCure Minimally Invasive Products 1157 1Positive Results Published Using AtriCure Minimally Invasive Products 1157 2Positive Results Published Using AtriCure Minimally Invasive Products 1157 3Positive Results Published Using AtriCure Minimally Invasive Products 1157 4Team Finds 118 Genes That Might Play Role in Cancer 9186 1Team Finds 118 Genes That Might Play Role in Cancer 9186 2Youth Suicide Warnings Are Slowing Antidepressant Sales 9181 1Youth Suicide Warnings Are Slowing Antidepressant Sales 9181 23M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 9176 13M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 9176 23M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 9176 3
... III Study Meets Primary Endpoint in,Rheumatoid Ar...or,Necrosis Factor Treatments -, NUTLEY, N.J., Jul...hat results from the Actemra Radiate (RheumAtoiD,A...fully met its,primary endpoint in patients with mo...led to respond to anti-tumor necrosis factor,treat...
...formation May Correlate with Clinical HbA1c,Reduct... Clinical,Trials --, PALO ALTO, Calif., July 9, 20... announced today that researchers have completed,p...zine increased,glucose stimulated insulin secretio...s using preclinical models of insulin,resistance, ...
Other Medicine Technology:Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 2Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 3Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis 4CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa 2CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of,Action for Ranexa 3
...ment software is a full-featured product capable o...e ophthalmic practice. This fully integrated solut...ve and clinical management needs of the eye care p...saVision can be implemented stand-alone or in an e...
The ReSeeVit Slit Lamp System is an easy-to-use digital video imaging system that captures anterior segment and retinal images for documentation, diagnosis and patient education. The package includes
The 2V slit lamp is a traditional style slit lamp that is designed with a vertical illumination tower and has standard 10X and 16X magnification. Revolutionary design provides increased optical effic
The ReSeeVit 3Z slit lamp is designed to for use with digital video imaging. This video ready slit lamp offers the popular horizontal style light source. It is another addition to the ReSeeVit family
Medicine Products: